Epidemiology of methicillin-resistant staphylococci in Europe

Clinical Microbiology and Infection

Volumn 9, Issue 12, 2003, Pages 1179-1186

  Stefani, S ^a   Varaldo, P E ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Methicillin resistant staphylococci; Molecular epidemiology

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; METICILLIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BIOFILM; BRAZIL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DEVICE INFECTION; EPIDEMIC; EUROPE; GENE CASSETTE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHY; HOSPITAL INFECTION; HUMAN; HUNGARY; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCANDINAVIA; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0345801072     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2003.00698.x     Document Type: Article

References (51)

1. Mulligan ME, Murray-Leisure KA, Ribner BS et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94: 313-28.
2. Jevons MP. 'Celbenin'-resistant staphylococci. BMJ 1961; i: 124-5.
3. Stewart JT, Holt RJ. Evolution of natural resistance to the newer penicillins. BMJ 1963; i: 308-11.
4. Benner EJ, Kayser FH. Growing clinical significance of methcillin-resistant Staphylococcus aureus. Lancet 1968; 2: 741-4.
5. Wenzel RP. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 440-2.
6. Projan SJ. Antibiotic resistance in the staphylococci. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. Gram-positive pathogens. Washington, DC: ASM Press, 2000: 463-70.
7. Carbon C. MRSA and MRSE: is there an answer? Clin Microbiol Infect 6(suppl 2): 17-22.
8. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
9. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States. MMWR 2002; 51: 565-7.
10. Moellering RC Jr. The specter of glycopeptide resistance: current trends and future considerations. Am J Med 1998; 104(suppl 5A): 3-6.
11. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7: 178-82.
12. Boyce JM. Are the epidemiology and microbiology of methicillin-resistant Staphylococcus aureus changing? JAMA 1998; 279: 623-4.
13. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 1998; 178: 577-80.
14. Fluckiger U, Widmer AF. Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy 1999; 45: 121-34.
15. Voss A, Milatovic D, Wallrauch-Schwartz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-5.
16. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32(suppl 2): 114-32.
17. Fluit AC, Wielders CLC, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY Study. J Clin Microbiol 2001; 39: 3727-32.
18. Vincent JL. Microbial resistance: lessons from EPIC study. European prevalence of infection. Intensive Care Med 2000; 26(suppl 1): S3-8.
19. Nicoletti G, Bonfiglio G, Bartoloni A et al. Distribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures from patients in three Italian intensive care units: a 2-year comparison. Int J Antimicrob Agents 2000; 15: 265-9.
20. Tomasz A. Accelerated evolution: emergence of multidrug resistant gram-positive bacterial pathogens in the 1990s. Neth J Med 1998; 52: 219-27.
21. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 10: 486-93.
22. Oliveira D, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2002; 2: 180-9.
23. Archer GL, Niemeyer DM. Original evolution of DNA associated with resistance to methicillin in staphylococci. Antimicrob Agents Chemother 1994; 2: 343-7.
24. Musser JM, Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol 1992; 30: 2058-63.
25. Enright M, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99: 7687-92.
26. Agodi A, Campanile F, Basile G, Viglianisi F, Stefani S. Phylogenetic analysis as a measure of genetic change in Staphylococcus aureus: the epidemiological impact of methicillin resistance. Eur J Epidemiol 1999; 15: 637-42.
27. van Belkum A. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains: state of affairs and tomorrow's possibilities. Microb Drug Resist 2000; 6: 173-88.
28. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008-15.
29. Roberts RB, de Lencastre H, Eisner W et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in 12 New York hospitals. MRSA Collaborative Study Group. J Infect Dis 1998; 178: 164-71.
30. Sá-Leão R, Santos Sanches I, Dias D, Peres I, Barros RM, de Lencastre H. Detection of an archaic clone of Staphylococcus aureus with low-level resistance to methicillin in a pediatric hospital in Portugal and in international samples: relics of a formerly widely disseminated strain? J Clin Microbiol 1999; 37: 1913-20.
31. Tomasz A, de Lencastre H. Molecular microbiology and epidemiology: coexistence or alliance? In: Wenzel RP, ed. Prevention and control of nosocomial infections, 3rd edn. Baltimore: Williams & Wilkins, 1997: 309-21.
32. Sanches IS, Ramirez M, Troni H et al. Evidence for the geographic spread of a methicillin-resistant Staphylococcus aureus clone between Portugal and Spain. J Clin Microbiol 1995; 33: 1243-6.
33. Oliveira D, Santos Sanches I, Mato R et al. Virtually all methicillin-resistant Staphylococcus aureus (MRSA) infections in the largest Portuguese teaching hospital are caused by two internationally spread multiresistant strains: the 'Iberian' and the 'Brazilian' clones of MRSA. Clin Microbiol Infect 1998; 4: 373-84.
34. Melter O, Santos Sanches I, Schindler J et al. Methicillin-resistant Staphylococcus aureus clonal types in the Czech Republic. J Clin Microbiol 1999; 37: 2798-803.
35. Campanile F, Mato R, Stefani S, Messina C, Santos Sanchez I, De Lencastre H. Molecular epidemiology of MRSA in Italy: clonal diffusion and evolution of polymorphisms in mecA and Tn554 regions [abstract T205]. In: Program and Abstracts of the 3rd European Congress of Chemotherapy, Madrid. Milan: ESCMID, 2000: 85.
36. Campanile F, Cafiso V, Cascone C, Gianninò V, Di Marco O, Stefani S. Clonal diffusion and evolution of mecA and Tn554 polymorphisms in methicillin-resistant Staphylococcus aureus in Italy. Infez Med 2001; 9: 30-8.
37. Kuroda M, Ohta T, Uchiyama I et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357: 1225-40.
38. Woodford N, Livermore DM. Can we beat MRSA now we know its genome sequence? Lancet Infect Dis 2001; 1: 9-10.
39. Huebner J, Goldmann DA. Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999; 50: 223-36.
40. Wenzel RP. Methicillin-resistant S. aureus and S. epidermidis strains: modern hospital pathogens. Infect Control 1986; 7: 118-19.
41. O'Gara JP, Humphreys H. Staphylococcus epidermidis biofilms: importance and implications. J Med Microbiol 2001; 50: 582-7.
42. Licking E. Getting a grip on bacterial slime. Business Week 13 September 1999; 98-100.
43. Frebourg NB, Lefebvre S, Baert S, Lemeland JF. PCR-based assay for discrimination between invasive and contaminating Staphylococcus epidermidis strains. J Clin Microbiol 2000; 38: 877-80.
44. Cafiso V, Campanile F, Santagati M, Di Bassiano F, Nicoletti G, Stefani S. L'espressione contemporanea di icaA e icaD determina la produzione di biofilm in S. epidermidis indipendentemente dalla loro fonte di isolamento. In: Program and Abstract Del 30° Congresso Nazionale Della Società Italiana Di Microbiologia, Catania. Catania: Societa Italiana. di Microbiologia (SIM), 2002: 114.
45. Froggatt JW, Johnston JL, Galetto DW, Archer GL. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 1989; 33: 460-6.
46. Schwalbe RS, Stapleton JT, Gilligan PH. Vancomycin-resistant staphylococcus. N Engl J Med 1987; 317: 766-8.
47. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000; 19: 403-17.
48. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100-7.
49. Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 2000; 44: 3122-6.
50. EARSS. Annual report 2001. Bilthoren: ESCMID, 2002.
51. Stefani S, Mezzatesta ML, Tempeta G et al. Comparative activity of Linezolid against Staphylococci and Enterococci isolated in Itlay. Clin Microbiol Infect 2002; 8: 368-372.